Skip to main content

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

Publication ,  Journal Article
Sands, BE; Kozarek, R; Spainhour, J; Barish, CF; Becker, S; Goldberg, L; Katz, S; Goldblum, R; Harrigan, R; Hilton, D; Hanauer, SB
Published in: ibdjournal
December 19, 2006

Natalizumab, a humanized monoclonal IgG4 antibody to α4 integrin, was investigated as a treatment of active Crohn's disease (CD). The safety of natalizumab given in combination with infliximab has not previously been studied.Seventy-nine adult patients with active CD (Crohn's Disease Activity Index [CDAI] score ≥ 150) despite ongoing infliximab treatment were randomized 2:1 to receive 3 intravenous infusions of natalizumab (300 mg; n = 52) or placebo (n = 27) every 4 weeks. Patients received infliximab (5 mg/kg) every 8 weeks for at least 10 weeks before randomization and throughout the study. The primary objective was to assess the short-term safety and tolerability of natalizumab in patients concurrently receiving infliximab. Secondary and tertiary objectives included measures of efficacy, health-related quality of life (HRQoL), and effects on inflammatory markers. A subset of patients also participated in a pharmacokinetic/pharmacodynamic (PK/PD) analysis of the effects of concurrent treatment.Incidence of adverse events (AEs) was similar in the treatment groups. AEs frequently reported in both groups were headache, CD exacerbation, nausea, and nasopharyngitis. No patient had a hypersensitivity-like reaction to natalizumab, whereas 4 patients (5%) experienced reactions to infliximab. Two patients (4%) developed anti-natalizumab antibodies; 10 patients (14%) developed anti-infliximab antibodies. The mean CDAI score decreased with natalizumab plus infliximab but was unchanged with infliximab alone (−37.7 versus +3.5; P = 0.084). Patients in both groups showed small increases in HRQoL (P = 0.811). No drug–drug interactions were noted.The combination of natalizumab plus infliximab was well tolerated. Several positive trends suggested that treating patients not in remission with infliximab plus natalizumab had greater efficacy than treatment with infliximab alone.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

ibdjournal

DOI

ISSN

1078-0998

Publication Date

December 19, 2006

Volume

13

Issue

1

Start / End Page

2 / 11

Related Subject Headings

  • Gastroenterology & Hepatology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sands, B. E., Kozarek, R., Spainhour, J., Barish, C. F., Becker, S., Goldberg, L., … Hanauer, S. B. (2006). Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Ibdjournal, 13(1), 2–11. https://doi.org/10.1002/ibd.20014
Sands, B. E., R. Kozarek, J. Spainhour, C. F. Barish, S. Becker, L. Goldberg, S. Katz, et al. “Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.” Ibdjournal 13, no. 1 (December 19, 2006): 2–11. https://doi.org/10.1002/ibd.20014.
Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. ibdjournal. 2006 Dec 19;13(1):2–11.
Sands, B. E., et al. “Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.” Ibdjournal, vol. 13, no. 1, Dec. 2006, pp. 2–11. Manual, doi:10.1002/ibd.20014.
Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. ibdjournal. 2006 Dec 19;13(1):2–11.

Published In

ibdjournal

DOI

ISSN

1078-0998

Publication Date

December 19, 2006

Volume

13

Issue

1

Start / End Page

2 / 11

Related Subject Headings

  • Gastroenterology & Hepatology
  • 1103 Clinical Sciences